⚠ Unsupported Browser ⚠
Our site probably won't work so great in Internet Explorer. Please try a more recent version of a major browser
like Chrome, Firefox, Safari, or Edge.
Reversing with Metformin Vascular Adverse Lesions (REMOVAL)
People with Type 1 diabetes are at increased risk of atherosclerosis (hardening of the arteries), which can lead to heart attacks, stroke and amputation. Paralleling the general population more people with Type 1 diabetes are overweight or obese, which is associated with the development of some feature such as insulin resistance and lipid (blood fat) problems more commonly associated with Type 2 diabetes. Because of this many groups are exploring the addition of glucose control treatments usually used in Type 2 diabetes care to the essential insulin for Type 1 diabetes. High heart disease risk adults with Type 1 diabetes were prescribed metformin vs. placebo for a mean of 3-years. Metformin was associated with slowing of artery damage (in the carotid arteries in the neck) and also reduced progression of kidney damage.
Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.
2017 The Lancet Diabetes & Endocrinology